The Filing Desk

Lexicon Pharmaceuticals

LXRX · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

LXRX · Last close · November 19, 2026
$1.67
Value Lexicon Pharmaceuticals yourself

Lexicon Pharmaceuticals' revenue rose 60.2% to $50 million in fiscal 2025. Its operating margin was −98.2%, up from −634.2% a year earlier. Free cash flow was −$68 million. The diluted share count rose 13.4%.

Lexicon Pharmaceuticals, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 5, 2026 · 0001062822-26-000050 Updated
Revenue
$50M
60.2%
Operating margin
−98.2%
536.0 pts
Net income
−$50M
 
Free cash flow
−$68M
 
Return on capital
−105.0%
 
Market cap
$743M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Lexicon Pharmaceuticals does

Lexicon Pharmaceuticals is a drug company with one approved product, INPEFA (sotagliflozin), a once-daily tablet approved in the U.S. in May 2023 to lower the risk of cardiovascular death and heart failure hospitalization in adults with heart failure or with type 2 diabetes, chronic kidney disease and other risk factors. It is also developing sotagliflozin as a treatment for hypertrophic cardiomyopathy, a condition in which the heart muscle thickens, in a late-stage trial called SONATA-HCM.

It is also seeking approval of the same drug, under the name ZYNQUISTA, for type 1 diabetes. The FDA issued complete response letters, which are refusals to approve as submitted, in March 2019 and December 2024. A public hearing process on whether there are grounds to deny approval is still going on. The company may resubmit its application if data from an outside study supports it.

Its third focus is pilavapadin, a pill for neuropathic pain, which is nerve pain. It reported positive results from two mid-stage trials in diabetic nerve pain, and it is looking for outside collaborators for its next steps. It puts most of its resources into research and into selling INPEFA.

Its biggest risks, as it describes them

  • Its drug programs may fail to finish development or to win approval.
  • Clinical trials may not show that its drugs are safe and effective.
  • The FDA process for approval is long and uncertain, as ZYNQUISTA's earlier rejections show.
  • It may not build a sales force and marketing system strong enough to sell its drugs.
From Lexicon Pharmaceuticals's annual report on Form 10-K, filed March 5, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Lexicon Pharmaceuticals lost money in fiscal 2025: a net loss of $50 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments8713817023896
Debt incl. finance leases04910010054
Net debt (negative means net cash)−87−90−70−138−42
Net debt to EBITDA—————
Debt to equity0.0x0.4x1.1x0.7x0.5x
Interest coverage−108.6x−36.2x−17.1x−15.3x−5.9x
Current ratio4.0x6.1x5.6x5.4x4.9x
Quick ratio4.0x6.1x5.6x5.4x4.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Lexicon Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Lexicon Pharmaceuticals says to expect

  • SONATA-HCM study: topline results timingLexicon continues to expect topline results in the first quarter of 2027.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $2.7 million of Lexicon Pharmaceuticals shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Feb 25, 2026Raymond DebbaneDirectorBought2,000$1.49$2,980Form 4
Feb 23, 2026Raymond DebbaneDirectorBought100,000$1.47$147,000Form 4
Feb 20, 2026Raymond DebbaneDirectorBought100,000$1.48$148,000Form 4
Feb 19, 2026Raymond DebbaneDirectorBought50,000$1.44$72,000Form 4
Feb 18, 2026Raymond DebbaneDirectorBought133,688$1.32$176,468Form 4
Feb 17, 2026Raymond DebbaneDirectorBought76,857$1.31$100,683Form 4
Feb 13, 2026Raymond DebbaneDirectorBought57,952$1.31$75,917Form 4
Feb 2, 2026Artal Group S.A.Director, 10% ownerBought1,538,462$1.30$2.0 millionForm 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score2 of 95 of 94 of 9
Rule of 40−12,719.4%1,903.0%−76.0%
Altman Z''−25.27−20.51−33.00
Accruals ratio−7.2%−8.2%7.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assetsFailPassPass
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsPassPassPass
F-score2 of 95 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Lexicon Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Lexicon PharmaceuticalsFY2560.2%−98.2%−136.2%−105.0%—4
Ocular TherapeutixFY25−18.5%−519.8%−417.5%——4Compare
Agios PharmaceuticalsFY2548.0%−873.9%−698.3%———Compare
IM CannabisFY251.3%−21.2%8.6%−64.9%——Compare
Nektar TherapeuticsFY25−43.9%−253.7%−377.8%——2Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue799263322240013150
Revenue growth−39.0%15.7%−31.1%409.5%−92.5%−98.8%−53.4%766.2%2,481.5%60.2%
Gross profit799061319220013050
Research and development164152100921545553598461
Operating income−127−131−103141−48−87−101−172−197−49
Net income−131−123−120130−59−88−102−177−200−50
Diluted EPS (US$)−1.27−1.17−1.141.16−0.53−0.60−0.62−0.80−0.63−0.14
Diluted shares (millions)104105106117111146166221320363
Cash flow
Cash from operations−176−185−149114−143−87−89−162−179−68
Capital expenditure0000011010
Free cash flow−176−186−149114−143−88−90−162−180−68
Dividends paid0000000000
Share buybacks1211131120
Acquisitions0000000000
Stock-based compensation8101214131112141412
Balance sheet at fiscal year end
Cash and short-term investments3463111602721528713817023896
Debt incl. finance leases1012522502491204910010054
Total assets476436284418204137194229298185
Total liabilities31836831030147237713615277
Shareholders' equity16868−2611715611411793146108
Margins and ratios
Gross margin100.0%97.9%96.1%99.0%92.0%100.0%100.0%92.9%98.0%99.5%
Operating margin−160.5%−142.5%−163.4%43.9%−199.2%−29,224.8%−72,489.2%−14,265.0%−634.2%−98.2%
Net margin−165.8%−134.1%−190.7%40.4%−244.1%−29,449.0%−73,341.0%−14,710.9%−644.8%−101.1%
Free cash flow margin−221.9%−202.4%−235.2%35.3%−596.2%−29,610.1%−64,875.5%−13,485.6%−578.5%−136.2%
Rule of 40 (growth + FCF margin)−260.9%−186.8%−266.3%444.9%−688.7%−29,708.8%−64,928.9%−12,719.4%1,903.0%−76.0%
Return on capital——−225.0%141.9%−68.8%−323.1%−293.6%−543.2%—−105.0%
Return on equity−58.0%−104.3%−576.0%287.0%−42.8%−65.0%−88.4%−168.5%−167.7%−39.7%
Return on assets−23.3%−27.0%−33.5%37.1%−18.9%−51.5%−61.6%−83.6%−75.9%−20.8%
Net debt to EBITDA———−0.2x——————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Lexicon Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Lexicon Pharmaceuticals.